BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20966402)

  • 21. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.
    Tello-Montoliu A; Marín F; Roldán V; Mainar L; López MT; Sogorb F; Vicente V; Lip GY
    J Intern Med; 2007 Dec; 262(6):651-8. PubMed ID: 17986200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome.
    Wollert KC; Kempf T; Peter T; Olofsson S; James S; Johnston N; Lindahl B; Horn-Wichmann R; Brabant G; Simoons ML; Armstrong PW; Califf RM; Drexler H; Wallentin L
    Circulation; 2007 Feb; 115(8):962-71. PubMed ID: 17283261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-ST elevation acute coronary syndromes?
    Correia LC; Lima JC; Rocha MS; D'Oliveira Junior A; Péricles Esteves J
    Clin Chim Acta; 2007 Jan; 375(1-2):124-8. PubMed ID: 16916502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes.
    Lopes RD; Starr A; Pieper CF; Al-Khatib SM; Newby LK; Mehta RH; Van de Werf F; Mahaffey KW; Armstrong PW; Harrington RA; White HD; Wallentin L; Granger CB
    Am J Med; 2010 Feb; 123(2):134-40. PubMed ID: 20103022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma markers of endothelial damage/dysfunction, inflammation and thrombogenesis in relation to TIMI risk stratification in acute coronary syndromes.
    Lee KW; Blann AD; Lip GY
    Thromb Haemost; 2005 Nov; 94(5):1077-83. PubMed ID: 16363252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of thrombolysis in myocardial infarction (TIMI)risk score in prognosis prediction in senior patient with acute coronary syndromes without ST elevation].
    Zhao MZ; Hu DY; Chen XY; Zhu TG; Xu YR
    Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(13):1103-4. PubMed ID: 15312512
    [No Abstract]   [Full Text] [Related]  

  • 28. Identification of potential outcome benefit from ACE inhibition after acute coronary syndrome: a biomarker approach using N-terminal proBNP.
    Squire I; Quinn P; Narayan H; Khan S; Dhillon O; Ng K; Kelly D; Davies J; Ng L
    Heart; 2010 Jun; 96(11):831-7. PubMed ID: 20478862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study.
    Bogaty P; Boyer L; Simard S; Dauwe F; Dupuis R; Verret B; Huynh T; Bertrand F; Dagenais GR; Brophy JM
    J Am Coll Cardiol; 2008 Jun; 51(24):2339-46. PubMed ID: 18549920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additive prognostic value of NT-proBNP over TIMI risk score in intermediate-risk patients with acute coronary syndrome.
    Eren NK; Ertaş F; Yüksek U; Cakir C; Nazli C; Köseoğlu M; Ergene O
    Turk Kardiyol Dern Ars; 2009 Jan; 37(1):1-8. PubMed ID: 19225247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
    Anand IS; Kempf T; Rector TS; Tapken H; Allhoff T; Jantzen F; Kuskowski M; Cohn JN; Drexler H; Wollert KC
    Circulation; 2010 Oct; 122(14):1387-95. PubMed ID: 20855664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stenting.
    Ketch TR; Turner SJ; Sacrinty MT; Lingle KC; Applegate RJ; Kutcher MA; Sane DC
    Am Heart J; 2008 Aug; 156(2):234-40. PubMed ID: 18657651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type D personality predicts clinical events after myocardial infarction, above and beyond disease severity and depression.
    Martens EJ; Mols F; Burg MM; Denollet J
    J Clin Psychiatry; 2010 Jun; 71(6):778-83. PubMed ID: 20156412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure.
    Kavsak PA; MacRae AR; Newman AM; Lustig V; Palomaki GE; Ko DT; Tu JV; Jaffe AS
    Clin Biochem; 2007 Mar; 40(5-6):326-9. PubMed ID: 17292342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.
    O'Donoghue M; de Lemos JA; Morrow DA; Murphy SA; Buros JL; Cannon CP; Sabatine MS
    Circulation; 2006 Aug; 114(6):550-7. PubMed ID: 16880323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 2-year follow-up of oxidative stress levels in patients with ST-segment elevation myocardial infarction: a subanalysis of the ALPS-AMI study.
    Abe N; Kashima Y; Izawa A; Motoki H; Ebisawa S; Miyashita Y; Imamura H; Ikeda U
    Angiology; 2015 Mar; 66(3):271-7. PubMed ID: 24642392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HDL-cholesterol level provides additional prognosis in acute coronary syndromes.
    Correia LC; Rocha MS; Esteves JP
    Int J Cardiol; 2009 Aug; 136(3):307-14. PubMed ID: 18706714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.